Anti-tumour necrosis factor-alpha treatment for perianal Crohn's disease in Australia

Burger, Daniel C., Lawrance, Ian C., Bampton, Peter A., Prosser, Ruth, Croft, Anthony, Gilshenan, Kristen, Radford-Smith, Graham L. and Florin, Timothy H. (2010) Anti-tumour necrosis factor-alpha treatment for perianal Crohn's disease in Australia. Medical Journal of Australia, 192 7: 375-377.

Author Burger, Daniel C.
Lawrance, Ian C.
Bampton, Peter A.
Prosser, Ruth
Croft, Anthony
Gilshenan, Kristen
Radford-Smith, Graham L.
Florin, Timothy H.
Title Anti-tumour necrosis factor-alpha treatment for perianal Crohn's disease in Australia
Formatted title
Anti-tumour necrosis factor-α treatment for perianal Crohn's disease in Australia
Journal name Medical Journal of Australia   Check publisher's open access policy
ISSN 0025-729X
Publication date 2010-04-05
Sub-type Article (original research)
Volume 192
Issue 7
Start page 375
End page 377
Total pages 3
Place of publication Sydney, NSW, Australia
Publisher Australasian Medical Publishing
Collection year 2011
Language eng
Formatted abstract
Objective: To examine the prevalence of perianal Crohn’s disease (PCD) and the eligibility of PCD patients to access anti-tumour necrosis factor-alpha (anti-TNFα) treatment under current Australian Pharmaceutical Benefits Scheme (PBS) guidelines.

Design, setting and participants:
A retrospective study of patients with Crohn’s disease (CD) and PCD attending four large adult inflammatory bowel disease (IBD) centres in Australia between January 2004 and May 2008. Patients for whom anti-TNFα therapy was clinically indicated were assessed to determine whether they satisfied PBS criteria for subsidised medication.

Main outcome measures: Prevalence of CD and PCD in patients attending different IBD centres; eligibility of PCD patients for PBS-subsidised anti-TNFα medication.

Results: Data were available on 3589 patients, representing about 6% of all patients with IBD in Australia. Of the 1815 patients with CD, 310 (17%) had PCD. Anti-TNFα therapy was deemed clinically indicated for 166 patients with PCD (54%), of whom 49 (30%) did not qualify for PBS-funded therapy.

Conclusion: Thirty per cent of patients with clinically significant PCD currently do not have access to PBS-subsidised optimal medical treatment. We believe that PBS criteria should be extended to include this subgroup of IBD patients.
Keyword Quality-of-life
Maintenance therapy
Activity index
Charm trial
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2011 Collection
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Sun, 09 May 2010, 00:02:37 EST